Trending Stock News

EPS for Cirrus Logic, Inc. (CRUS) Expected At $1.63; Ultragenyx Pharmaceutical Has 1.19 Sentiment

Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company has market cap of $2.04 billion. The firm is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It currently has negative earnings. The Company’s biologics product candidates also comprise recombinant human beta -glucuronidase , an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis.

Analysts expect Cirrus Logic, Inc. (NASDAQ:CRUS) to report $1.63 EPS on February, 7.They anticipate $0.13 EPS change or 7.39% from last quarter’s $1.76 EPS. CRUS’s profit would be $103.77 million giving it 8.10 P/E if the $1.63 EPS is correct. After having $1.22 EPS previously, Cirrus Logic, Inc.’s analysts see 33.61% EPS growth. The stock increased 0.96% or $0.5 during the last trading session, reaching $52.84. About 531,770 shares traded. Cirrus Logic, Inc. (NASDAQ:CRUS) has risen 97.50% since January 14, 2017 and is uptrending. It has outperformed by 80.80% the S&P500.

Since August 2, 2017, it had 0 insider purchases, and 16 insider sales for $7.97 million activity. SCHUELE ALAN R had sold 2,000 shares worth $114,600 on Monday, August 7. $27,960 worth of Cirrus Logic, Inc. (NASDAQ:CRUS) was sold by KING CHRISTINE. SHERMAN WILLIAM D also sold $10,024 worth of Cirrus Logic, Inc. (NASDAQ:CRUS) shares. On Tuesday, August 22 Brannan Andrew sold $1.18 million worth of Cirrus Logic, Inc. (NASDAQ:CRUS) or 21,504 shares. On Tuesday, August 22 the insider Hughes Allan sold $813,220. Tupman David J. sold $67,789 worth of stock or 1,024 shares. CASE THURMAN K had sold 8,610 shares worth $493,784.

Among 15 analysts covering Cirrus Logic (NASDAQ:CRUS), 10 have Buy rating, 2 Sell and 3 Hold. Therefore 67% are positive. Cirrus Logic had 40 analyst reports since July 23, 2015 according to SRatingsIntel. Oppenheimer upgraded Cirrus Logic, Inc. (NASDAQ:CRUS) rating on Thursday, January 28. Oppenheimer has “Outperform” rating and $40 target. The rating was upgraded by Pacific Crest to “Overweight” on Tuesday, April 4. As per Friday, January 8, the company rating was maintained by Stifel Nicolaus. Canaccord Genuity maintained the shares of CRUS in report on Wednesday, August 2 with “Buy” rating. On Thursday, August 3 the stock rating was maintained by Susquehanna with “Buy”. On Wednesday, August 2 the stock rating was maintained by Stifel Nicolaus with “Buy”. The stock of Cirrus Logic, Inc. (NASDAQ:CRUS) earned “Buy” rating by KeyBanc Capital Markets on Thursday, August 31. The firm earned “Hold” rating on Friday, November 3 by Craig Hallum. Stifel Nicolaus maintained Cirrus Logic, Inc. (NASDAQ:CRUS) on Thursday, October 13 with “Buy” rating. Stifel Nicolaus maintained Cirrus Logic, Inc. (NASDAQ:CRUS) on Friday, December 29 with “Buy” rating.

Cirrus Logic, Inc., a fabless semiconductor company, develops, makes, and markets analog and mixed-signal integrated circuits for a range of consumer and industrial markets. The company has market cap of $3.36 billion. The firm offers portable and non-portable audio, and other products. It has a 12.96 P/E ratio. The Company’s products include analog and mixed-signal audio converters, and digital signal processing products for mobile applications; codecs-chips that integrate analog-to-digital converters and digital-to-analog converters into a single IC; smart codecs, a codec with digital signal processer; amplifiers; micro-electromechanical systems microphones; digital interface products; and standalone digital signal processors.

Investors sentiment increased to 1.02 in Q3 2017. Its up 0.08, from 0.94 in 2017Q2. It increased, as 36 investors sold Cirrus Logic, Inc. shares while 105 reduced holdings. 52 funds opened positions while 92 raised stakes. 55.67 million shares or 1.96% less from 56.78 million shares in 2017Q2 were reported. Moreover, Campbell Invest Adviser Ltd Llc has 0.2% invested in Cirrus Logic, Inc. (NASDAQ:CRUS) for 4,712 shares. Vident Investment Advisory Lc holds 0.11% of its portfolio in Cirrus Logic, Inc. (NASDAQ:CRUS) for 39,702 shares. Tortoise Management Ltd Liability Company holds 0% of its portfolio in Cirrus Logic, Inc. (NASDAQ:CRUS) for 139 shares. Stifel Fincl Corp holds 8,346 shares or 0% of its portfolio. Bnp Paribas Arbitrage holds 0% or 33,773 shares in its portfolio. American Group Incorporated reported 173,790 shares. Tompkins Finance reported 0% stake. Balyasny Asset Mngmt Ltd Llc invested in 0.01% or 47,940 shares. 9,785 are owned by Hightower Advsr Limited Liability. Geode Cap Mngmt Lc has 0.02% invested in Cirrus Logic, Inc. (NASDAQ:CRUS) for 837,474 shares. Wright Invsts Serv Inc invested 0.18% of its portfolio in Cirrus Logic, Inc. (NASDAQ:CRUS). The Colorado-based Alps has invested 0% in Cirrus Logic, Inc. (NASDAQ:CRUS). 175,548 were accumulated by Hillcrest Asset Mngmt Lc. 121,713 were accumulated by Panagora Asset Management. James Inv Rech stated it has 0.06% in Cirrus Logic, Inc. (NASDAQ:CRUS).

Ratings analysis reveals 0 of Ultragenyx Pharma’s analysts are positive. Out of 2 Wall Street analysts rating Ultragenyx Pharma, 0 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. RARE was included in 2 notes of analysts from November 14, 2016. Citigroup downgraded the shares of RARE in report on Monday, November 14 to “Sell” rating. The firm has “Hold” rating by Jefferies given on Thursday, April 6.

Analysts await Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to report earnings on February, 15. They expect $-2.00 earnings per share, down 14.29% or $0.25 from last year’s $-1.75 per share. After $-1.87 actual earnings per share reported by Ultragenyx Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts 6.95% negative EPS growth.

Iguana Healthcare Management Llc holds 1.49% of its portfolio in Ultragenyx Pharmaceutical Inc. for 50,000 shares. Abingworth Llp owns 38,100 shares or 1.4% of their US portfolio. Moreover, Columbia Wanger Asset Management Llc has 1.26% invested in the company for 1.60 million shares. The California-based Capital International Ltd Ca has invested 0.94% in the stock. Rhenman & Partners Asset Management Ab, a Sweden-based fund reported 100,000 shares.

The stock decreased 0.77% or $0.37 during the last trading session, reaching $47.8. About 343,241 shares traded. Ultragenyx Pharmaceutical Inc. (RARE) has declined 6.49% since January 14, 2017 and is downtrending. It has underperformed by 23.19% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *